Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

WhatsApp Embedded in Routine Service Delivery for Smoking Cessation

20 ottobre 2018 aggiornato da: Seyfi Durmaz, Ege University

WhatsApp Embedded in Routine Service Delivery for Smoking Cessation: Effects on Success Rates in a Randomized Controlled Study

Background: Recently, the use of communication technologies and social media applications has become increasingly widespread to strengthen efforts for smoking cessation. The purpose of this study is; to assess the effect on success rate of the WhatsApp application which is embedded in the smoking cessation policlinic service delivery.

Materials and Methods: A randomized controlled intervention study was conducted with 132 volunteers who were followed up at the EUTF Smoking Cessation Policlinic between March-July 2017. The intervention content based on transtheoretic model was prepared and 60 WhatsApp messages were delivered to participants for 3 months of follow up. For data collection, initial interview form and follow up form consisting sociodemographic characteristics, smoking status, medical condition and treatment, were used. The success rate at first and third months were assessed by the point-prevalence regarding the previous week. Intention-to-treat analysis was used. For secondary outcomes; number of follow-ups, change in weight and continuity of medication were evaluated.

Findings: Success rate in the first month was 65.9% for intervention group and 40.9% in the control group; for the third month it was 50.0% in the intervention group and 30.7% in the control group. Being in the intervention group increased the success rate by 3,50 (1,30-9,44) times in the first month and 2,50 (1,08-6,40) times in the third month. The intervention was the only parameter effective in the two follow-up periods; the difference in success rate caused by gender, marital status and work-related social class has been eliminated after adjustment for the intervention.

Panoramica dello studio

Descrizione dettagliata

Trial design

The study was designed as a RCT including two parallel arms: an intervention group receiving messages through WhatsApp Messenger operating on smart phones and a control group not receiving these messages. Both groups received the standard outpatient care of the clinic including aproximately 45 minutes face-to-face individual counseling at first contact ending with the decision of treatment and quit date, and a support booklet on quitting and subsequent follow-ups by the same clinician at 1st, 2nd, 4th weeks and 3rd month after quit date, either face-to-face at the clinic or by telephone if the patient does not come to the clinic for follow-up. The study was carried out in the smoking cessation clinic of Ege University Medical School's Public Health Department.

Sample size

An a priori power analysis was conducted with OpenEpi, Version 3 by selecting a two-sided test to compare 30% success in the control group at 1st month versus 60% success rate in the intervention group with an error margin of 5%, a power of 80% and an allocation ratio of 1:2 which yielded a minimum sample size of 36 in the intervention and 72 in the control groups. For possible loss to follow-up, the sample sizes were increased by 20% to 43 and 86, respectively.

Randomization

Among the 132 participants included in the study, 44 were randomly allocated to the intervention arm and 88 were randomly allocated to the control group. Among the intervention group , there were no losses to follow-up at 1st and 3rd months, but two participants have requested the cessation of the intervention after their 1st month follow-up.

Blinding

The study was single-blind as blinding of the helthcare providers to intervention assignment was achieved and the physicians conducted usual care for smoking cessation counseling.The physicians were blind throughout the follow ups as well. However, participants and the researcher who sent the messages were not blind.

Variables

Primary outcome variables: Quitting success rates at the end of the 1st, 3rd and 6th month of follow-up in the intervention and control groups. Quitting success rate at 1st month was calculated with point prevalence. History of cessation was based on self report and those who declared not smoked even a single puff on a cigarette at all in the past two weeks were considered as "successful" in the quitting attempt. The success rate at 3rd month was calculated with point prevalence. In this point, not smoking at all in total in the past ten weeks was considered "successful" in the quitting attempt. The success rate at 6th month was calculated with point prevalence. In this point, not smoking at all in total in the past 24 weeks was considered "successful" in the quitting attempt.

Secondary outcome variables: The total number of follow-ups in the 1st, 3rd and 6th month. Contacts were divided into two categories: face-to face contacts and telephone calls. The total number of routine follow-ups was classified as adequate when 3 or more in the 1st month and a total of 4 follow-ups was considered as adequate at 3rd month. At 1st month, at least one of these follow-ups was required to be face-to-face for adequacy. The continuity to drug/NRT therapy was categorized as <1 month or ≥1 month. Any change in weight was categorized as; has weight gain, no weight gain

Data collection Data collection was conducted at the Smoking Cessation Clinic of the Public Health Department at Ege University Medical School Hospital between March 2017-March 2018. The intended number of participants was achieved in 4.5 months and with the completion of the last follow-up, the study was finalized.

Analysis

The analyses were conducted according to the Intention-To-Treat (ITT) principle. The participants lost to follow-up were considered unsuccessful in quitting, as non-response could be expected in relapsing individuals, thus Last Observation Carried Forward (LOCF) was not used.

Smoking cessation successes in the groups were compared with the incidences and relative efficacy of the intervention. Chi-square test, Student's t test in independent groups, single and multivariate logistic regression (enter method) were used for analyses. The multivariate analysis of factors associated with smoking cessation success was performed by using logistic regression analysis with two models. In the first model the investigators controlled for age and gender, in the second model controlling was for age, gender and all the other associated variables in univariate analyses. Analyses were made separately for the 1st, 3rd and 6th month. Statistical significance was set at p<0.05.

Ethical issues

The study was approved by Ege University Medical School's institutional review board (decision no.16-12.1/11 on January 6, 2017). Written informed consent of every participant to enroll and receive WhatsApp messages were also obtained with confidentiality for name and address. With the blinding procedures described above, the delivery of routine service for all participants regardless of the allocation to intervention or control group was ensured.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

127

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • İzmir, Tacchino, 35100
        • Ege University Faculty of Nedicine Public Health Departmant

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Among patients applying to the smoking cessation outpatient clinic between March and October 2017,
  • >18-year old volunteers who smoked at least one cigarette/day,
  • using WhatsApp at least on four days of the week,
  • accepting the 3-month follow-up were included in the study.

Exclusion Criteria:

  • Besides people who did not meet the inclusion criteria, other patients applying to the clinic but who were referred to another centre without receiving any treatment,
  • people who were not 'ready to quit' according to the TTM stages of change evaluation
  • who had already quit before applying to the clinic were excluded.
  • If two or more patients were living in the same house or had applied to the clinic together, only the first of these was included and the rest were excluded from the study, as they could show the arriving messages to their friend/ partner/ relative.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Doppio

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Receiving WhatsApp messages
Among patients applying to the smoking cessation outpatient clinic between March and October 2017, >18-year old volunteers who smoked at least one cigarette/day, using WhatsApp at least on four days of the week, accepting the 3-month follow-up were included In receiving WhatsApp messages group.
The routine service delivery was ongoing as the intervention was conducted. In addition to the routine procedures in service delivery described above, WhatsApp messages were sent according to the plan.
Nessun intervento: Not receiving WhatsApp messages
In "not receiving WhatsApp messages" group; Stratification and randomization were both used to randomly allocate participants to both arms of the study. The intervention and control groups were first stratified according to physician and then gender, and later allocated in a simple random manner. Randomization was conducted using a computer spreadsheet. Allocation according to gender was conducted regarding the 2:3 female to male ratio in the routine cessation services and stratification according to physician aimed to have a balanced distribution among the different physicians working in the same cessation unit. As the target number of participants was small, further stratification was not applied. Simple random sampling was then used to allocate participants to each group.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Quitting success rates at the end of the 1st, 3rd and 6th month
Lasso di tempo: 6 months

Quitting success rates at the end of the 1st, 3rd and 6th month of follow-up in the intervention and control groups. Quitting success rate at 1st month was calculated with point prevalence. History of cessation was based on self report and those who declared not smoked even a single puff on a cigarette at all in the past two weeks were considered as "successful" in the quitting attempt (19). The success rate at 3rd month was calculated with point prevalence. In this point, not smoking at all in total in the past ten weeks was considered "successful" in the quitting attempt. The success rate at 6th month was calculated with point prevalence. In this point, not smoking at all in total in the past 24 weeks was considered "successful" in the quitting attempt.

A decrease in success rates at six months is expected in comparison with 3 months as the intervention lasts for 3 months.

6 months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
The total number of follow-ups
Lasso di tempo: 3 months
The total number of follow-ups in the 1st, 3rd month. Contacts were divided into two categories: face-to face contacts and telephone calls. The total number of routine follow-ups was classified as adequate when 3 or more in the 1st month and a total of 4 follow-ups was considered as adequate at 3rd month. At 1st month, at least one of these follow-ups was required to be face-to-face for adequacy.
3 months
The continuity to drug,
Lasso di tempo: 3 months
The continuity to drug/NRT therapy was categorized as using the prescribed drug for <1 month or ≥1 month.
3 months
Self reported difference in weight in kilograms since the first contact
Lasso di tempo: 3 months
Any increase in weight (kg) was categorized as; has weight gain, no weight gain.
3 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

1 marzo 2017

Completamento primario (Effettivo)

1 giugno 2017

Completamento dello studio (Effettivo)

1 ottobre 2017

Date di iscrizione allo studio

Primo inviato

4 settembre 2018

Primo inviato che soddisfa i criteri di controllo qualità

19 ottobre 2018

Primo Inserito (Effettivo)

22 ottobre 2018

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

23 ottobre 2018

Ultimo aggiornamento inviato che soddisfa i criteri QC

20 ottobre 2018

Ultimo verificato

1 ottobre 2018

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 16-12.1/11

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

No

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Smettere di fumare

Sottoscrivi